

Announcement

DKSH and Sumitomo Dainippon Pharma bring lurasidone hydrochloride to three Asian markets

DKSH, the leading Market Expansion Services provider with a focus on Asia, and Sumitomo Dainippon Pharma Co., Ltd. have made lurasidone hydrochloride (HCl), an atypical antipsychotic drug, available to patients in Thailand, Singapore and Hong Kong.

Bangkok, October 18, 2017 – DKSH Business Unit Healthcare, a leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, has started the commercialization in Thailand, Singapore and Hong Kong of lurasidone HCl, created by Sumitomo Dainippon Pharma Co., Ltd. The product, indicated for the treatment of schizophrenia, will be available for prescription by healthcare prescribers in hospitals and clinics.

The launch follows the successful registration of the product, a process led by DKSH's team of regulatory experts. DKSH will now provide marketing, sales, distribution and logistics services across the three markets, under license from Sumitomo Dainippon Pharma, and in collaboration with Sumitomo Dainippon Pharma's United States (US) affiliate Sunovion Pharmaceuticals Inc.

Lurasidone HCl is a prescription drug in tablet form first approved in the US for the treatment of adult patients with schizophrenia. According to the World Health Organization, more than 21 million people suffer from this severe mental disorder, characterized by profound disruptions in thinking and affecting language, perception and the sense of self. The disability-adjusted life year (DALY) rate suggests that the impact of schizophrenia is highest in Asian countries¹.

"Following successful introductions of our lurasidone HCl product in western markets, this collaboration with DKSH in three Asian markets helps extend our contribution to the treatment of patients, leveraging DKSH's wide range of services and dedication to excellence," said Kenji Toba, Senior Director, International Business Management, Sumitomo Dainippon Pharma.

"Supporting Sumitomo Dainippon Pharma in Thailand, Singapore and Hong Kong brings us one step closer to our mission of providing patients in Asia with access to better treatment options. With the largest dedicated salesforce in Asia and a broad reach across channels, we are committed to driving Asian expansion for Sumitomo Dainippon Pharma. This in turn will help grow inner Asian trade," added Bijay Singh, Global Head, Business Unit Healthcare, DKSH.

About lurasidone HCl

Lurasidone hydrochloride (HCl) is an atypical antipsychotic created originally by Sumitomo Dainippon Pharma, characterized by a unique chemical structure and an affinity for dopamine D₂, serotonin 5-HT_{2A} and serotonin 5-HT₇ receptors where it has antagonist effects. In addition, lurasidone is a partial agonist at the serotonin 5-HT_{1A} receptor and has no appreciable affinity for histamine H₁ or muscarinic M₁ receptors. Lurasidone has been available for the treatment of schizophrenia in the US since 2011, in Canada since 2012, in Switzerland since 2013, in Denmark, Norway and the U.K. since 2014, in the Netherlands, Finland and Australia since 2015, and in Sweden since 2016. Lurasidone has been available for the treatment of bipolar I depression in the US since 2013, and in Canada since 2014. Sumitomo Dainippon Pharma is conducting Phase 3 studies with a view to obtaining approvals of lurasidone for the treatment of schizophrenia, bipolar I depression and bipolar maintenance in Japan and submitted the New Drug Application for the treatment of schizophrenia in China. Similar efforts are ongoing in collaboration with Daiichi Sankyo Company, Limited for four Latin American countries, with Standard Chem. & Pharm. Co., Ltd. for Taiwan, with Servier Laboratories Australia Pty Ltd. for Australia and with NewBridge Pharmaceuticals Limited for the six countries of the Gulf Cooperation Council including Saudi Arabia and Kuwait.

¹ Ayuso-Mateos, J.L. (2006), 'Global burden of schizophrenia in the year 2000', Geneva; World Health Organization

About Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan operating globally in major pharmaceutical markets, including Japan, the United States, China and the European Union. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area and the Oncology area, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has about 6,500 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at <http://www.ds-pharma.com/>.

About Sunovion Pharmaceuticals Inc. (Sunovion)

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion's vision is to lead the way to a healthier world. The company's spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions. Sunovion's track record of discovery, development and/or commercialization of important therapies has included Utibron™ Neohaler® (indacaterol/glycopyrrolate) inhalation powder, Brovana® (arformoterol tartrate) inhalation solution, Latuda® (lurasidone HCl) and Aptiom® (eslicarbazepine acetate).

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company's web sites: www.sunovion.com, www.sunovion.eu and www.sunovion.ca. Connect with Sunovion on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 780 business locations in 36 countries – 750 of them in Asia – and 30,320 specialized staff, DKSH generated net sales of CHF 10.5 billion in 2016. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.

DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, capillary physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With 120 business locations in 13 countries and around 9,740 specialized staff, Business Unit Healthcare serves over 150,000 customers and generated net sales of CHF 5.5 billion in 2016.

For further information please contact:

DKSH Healthcare

Kalle Siebring
Manager, Group Communications
Business Unit Consumer Goods and Healthcare
Phone +66 2 220 9739
kalle.siebring@dksh.com